OMER•benzinga•
Omeros' Narsoplimab Met Pivotal Trial Primary Endpoint; Given These Results, Omeros Will Resubmit To FDA As Soon As Possible Its Narsoplimab Biologics License Application For TA-TMA
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on December 19, 2024 by benzinga